| Year |
Citation |
Score |
| 2023 |
Lichtenberg FR. Has pharmaceutical innovation reduced the average cost of U.S. health care episodes? International Journal of Health Economics and Management. PMID 37940731 DOI: 10.1007/s10754-023-09363-y |
0.351 |
|
| 2023 |
Lichtenberg FR. Number of drugs provided by the Pharmaceutical Benefits Scheme and mortality and hospital utilization in Australia, 2002-2019. Ssm - Population Health. 24: 101514. PMID 37731531 DOI: 10.1016/j.ssmph.2023.101514 |
0.325 |
|
| 2022 |
Lichtenberg FR. The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries. Economics and Human Biology. 46: 101124. PMID 35344806 DOI: 10.1016/j.ehb.2022.101124 |
0.382 |
|
| 2020 |
Blankart KE, Lichtenberg FR. Are patients more adherent to newer drugs? Health Care Management Science. PMID 32770286 DOI: 10.1007/S10729-020-09513-5 |
0.423 |
|
| 2020 |
Lichtenberg FR. How cost-effective are new cancer drugs in the U.S.? Expert Review of Pharmacoeconomics & Outcomes Research. 1-17. PMID 31906739 DOI: 10.1080/14737167.2020.1709965 |
0.45 |
|
| 2019 |
Lichtenberg FR. The impact of pharmaceutical innovation on the burden of disease in Canada, 2000-2016. Ssm - Population Health. 8: 100457. PMID 31440578 DOI: 10.1016/J.Ssmph.2019.100457 |
0.472 |
|
| 2019 |
Lichtenberg FR. The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis. Forum For Health Economics & Policy. PMID 31017868 DOI: 10.1515/Fhep-2018-0009 |
0.453 |
|
| 2019 |
Lichtenberg FR. How many life-years have new drugs saved? A three-way fixed-effects analysis of 66 diseases in 27 countries, 2000-2013. International Health. PMID 30912800 DOI: 10.1093/Inthealth/Ihz003 |
0.418 |
|
| 2019 |
Lichtenberg FR. The impact of access to prescription drugs on disability in eleven European countries. Disability and Health Journal. PMID 30709771 DOI: 10.1016/J.Dhjo.2019.01.003 |
0.409 |
|
| 2019 |
Lichtenberg FR. The long-run impact of new medical ideas on cancer survival and mortality Economics of Innovation and New Technology. 28: 722-740. DOI: 10.1080/10438599.2018.1557421 |
0.312 |
|
| 2018 |
Lichtenberg FR. The Impact of Public and Private Research on Premature Cancer Mortality and Hospitalization in the United States, 1999-2013: The American Economist. 63: 147-165. DOI: 10.1177/0569434518760537 |
0.342 |
|
| 2018 |
Lichtenberg FR. The impact of pharmaceutical innovation on cancer mortality in Russia, 2001–2011 Journal of Pharmaceutical Health Services Research. 9: 79-89. DOI: 10.1111/Jphs.12219 |
0.316 |
|
| 2017 |
Lichtenberg FR. The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia Economic Record. 93: 353-378. DOI: 10.1111/1475-4932.12332 |
0.457 |
|
| 2017 |
Lichtenberg FR, Tatar M, Çalışkan Z. The impact of pharmaceutical innovation on health outcomes and utilization in Turkey: A re-examination Health Policy and Technology. 6: 226-233. DOI: 10.1016/J.Hlpt.2017.01.003 |
0.429 |
|
| 2017 |
Lichtenberg FR. The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013 Latin American Economic Review. 26: 1-22. DOI: 10.1007/S40503-017-0045-6 |
0.442 |
|
| 2016 |
Lichtenberg FR. The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004-2012. Forum For Health Economics & Policy. 20. PMID 31419903 DOI: 10.1515/Fhep-2015-0042 |
0.457 |
|
| 2015 |
Lichtenberg FR. The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011. International Journal of Health Economics and Management. 15: 339-359. PMID 27878681 DOI: 10.1007/S10754-015-9172-2 |
0.472 |
|
| 2015 |
Lichtenberg FR. The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. PMID 26342826 DOI: 10.1007/S10198-015-0725-6 |
0.468 |
|
| 2015 |
Hostenkamp G, Lichtenberg FR. The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Social Science & Medicine (1982). 130: 162-71. PMID 25703669 DOI: 10.1016/J.Socscimed.2015.02.003 |
0.41 |
|
| 2015 |
Lichtenberg FR. The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010. Applied Health Economics and Health Policy. 13: 207-22. PMID 25564200 DOI: 10.1007/S40258-014-0144-3 |
0.345 |
|
| 2015 |
Hostenkamp G, Lichtenberg FR. Listen to Your Doctor, or Else!: Medication Under-Use and Overuse and Long-Term Health Outcomes of Danish Diabetes Patients National Bureau of Economic Research. DOI: 10.3386/W21780 |
0.335 |
|
| 2015 |
Lichtenberg FR. Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995–2010 International Journal of the Economics of Business. 22: 277-299. DOI: 10.1080/13571516.2015.1045743 |
0.437 |
|
| 2015 |
Lichtenberg F, Laires P. The Impact Of Pharmaceutical Innovation On Longevity In Portugal, 2002-2010. Value in Health. 18. DOI: 10.1016/J.Jval.2015.09.1684 |
0.308 |
|
| 2015 |
Lichtenberg F, Laires P. The Impact Of Pharmaceutical Innovation On Premature Cancer Mortality In Portugal Value in Health. 18. DOI: 10.1016/J.Jval.2015.09.1214 |
0.308 |
|
| 2014 |
Lichtenberg FR, Tatar M, Çalışkan Z. The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999-2010. Health Policy (Amsterdam, Netherlands). 117: 361-73. PMID 24996837 DOI: 10.1016/J.Healthpol.2014.06.002 |
0.422 |
|
| 2014 |
Lichtenberg FR. The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009. Economics and Human Biology. 13: 107-27. PMID 23664114 DOI: 10.1016/J.Ehb.2013.04.002 |
0.466 |
|
| 2014 |
Lichtenberg FR. Has medical innovation reduced cancer mortality Cesifo Economic Studies. 60: 135-177. DOI: 10.1093/Cesifo/Ift014 |
0.379 |
|
| 2014 |
Lichtenberg FR. The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010 Journal of Human Capital. 8: 432-480. DOI: 10.1086/679110 |
0.368 |
|
| 2014 |
Lichtenberg FR, Pettersson B. The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data Economics of Innovation and New Technology. 23: 239-273. DOI: 10.1080/10438599.2013.828456 |
0.473 |
|
| 2014 |
Lichtenberg FR. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009 Health Policy and Technology. 3: 36-58. DOI: 10.1016/J.Hlpt.2013.09.005 |
0.43 |
|
| 2013 |
Lichtenberg FR. The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files. Forum For Health Economics & Policy. 16: 1-33. PMID 31419866 DOI: 10.1515/fhep-2012-0032 |
0.38 |
|
| 2013 |
Lichtenberg FR. The impact of therapeutic procedure innovation on hospital patient longevity: evidence from Western Australia, 2000-2007. Social Science & Medicine (1982). 77: 50-9. PMID 23206558 DOI: 10.1016/J.Socscimed.2012.11.004 |
0.37 |
|
| 2013 |
Lichtenberg FR. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999-2007. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. 14: 41-56. PMID 21953319 DOI: 10.1007/S10198-011-0349-4 |
0.462 |
|
| 2012 |
Lichtenberg FR. Contribution of pharmaceutical innovation to longevity growth in Germany and France, 2001-7. Pharmacoeconomics. 30: 197-211. PMID 22283691 DOI: 10.2165/11587150-000000000-00000 |
0.458 |
|
| 2012 |
Duflos G, Lichtenberg FR. Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization International Review of Law and Economics. 32: 95-109. DOI: 10.1016/J.Irle.2011.08.003 |
0.389 |
|
| 2011 |
Lichtenberg FR. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being. Health Affairs (Project Hope). 30: 1539-44. PMID 21821571 DOI: 10.1377/Hlthaff.2010.0891 |
0.408 |
|
| 2011 |
Lichtenberg FR. Despite steep costs, payments for new cancer drugs make economic sense. Nature Medicine. 17: 244. PMID 21383714 DOI: 10.1038/Nm0311-244 |
0.397 |
|
| 2011 |
Sampat BN, Lichtenberg FR. What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Affairs (Project Hope). 30: 332-9. PMID 21289355 DOI: 10.1377/Hlthaff.2009.0917 |
0.405 |
|
| 2011 |
Lichtenberg FR. The quality of medical care, behavioral risk factors, and longevity growth. International Journal of Health Care Finance and Economics. 11: 1-34. PMID 21188512 DOI: 10.1007/S10754-010-9086-Y |
0.332 |
|
| 2011 |
Lichtenberg FR. Has Pharmaceutical Innovation Reduced Social Security Disability Growth International Journal of the Economics of Business. 18: 293-316. DOI: 10.1080/13571516.2011.584432 |
0.414 |
|
| 2010 |
Lichtenberg FR. The effect of drug vintage on survival: micro evidence from Puerto Rico's Medicaid program. Advances in Health Economics and Health Services Research. 22: 273-92. PMID 20575237 DOI: 10.1108/S0731-2199(2010)0000022015 |
0.441 |
|
| 2010 |
Lichtenberg FR. Pharmaceutical Price Discrimination and Social Welfare Capitalism and Society. 5: 1-32. DOI: 10.2202/1932-0213.1066 |
0.442 |
|
| 2010 |
Lichtenberg FR. Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia Forum For Health Economics & Policy. 13: 1-18. DOI: 10.2202/1558-9544.1202 |
0.334 |
|
| 2009 |
Lichtenberg FR. Do new drugs save lives? Journal of General Internal Medicine. 24: 1356; author reply 1. PMID 19756872 DOI: 10.1007/S11606-009-1101-Y |
0.399 |
|
| 2009 |
Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P. The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 847-56. PMID 19490554 DOI: 10.1111/J.1524-4733.2009.00532.X |
0.458 |
|
| 2009 |
Lichtenberg FR. Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003. Health Economics. 18: 519-34. PMID 18634121 DOI: 10.1002/Hec.1382 |
0.448 |
|
| 2009 |
Lichtenberg FR. International differences in cancer survival rates: the role of new drug launches International Journal of Healthcare Technology and Management. 10: 138-155. DOI: 10.1504/Ijhtm.2009.025818 |
0.389 |
|
| 2009 |
Lichtenberg FR. The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978–2004 Economics of Innovation and New Technology. 18: 407-428. DOI: 10.1080/10438590802547142 |
0.413 |
|
| 2008 |
Lichtenberg FR, Duflos G. Pharmaceutical innovation and the longevity of Australians: a first look. Advances in Health Economics and Health Services Research. 19: 95-117. PMID 19548515 DOI: 10.1016/S0731-2199(08)19005-7 |
0.465 |
|
| 2008 |
Lichtenberg FR. Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data Forum For Health Economics & Policy. 10: 1-27. DOI: 10.2202/1558-9544.1090 |
0.372 |
|
| 2007 |
Lichtenberg FR, Sun SX. The impact of Medicare Part D on prescription drug use by the elderly. Health Affairs (Project Hope). 26: 1735-44. PMID 17978393 DOI: 10.1377/Hlthaff.26.6.1735 |
0.434 |
|
| 2007 |
Lichtenberg FR. Effects of new drugs on overall health spending: Frank Lichtenberg responds. Health Affairs (Project Hope). 26: 887-90. PMID 17485771 DOI: 10.1377/Hlthaff.26.3.887 |
0.414 |
|
| 2007 |
Lichtenberg FR. The Impact of New Drugs on US Longevity and Medical Expenditure, 1990–2003: Evidence from Longitudinal, Disease-Level Data The American Economic Review. 97: 438-443. DOI: 10.1257/Aer.97.2.438 |
0.444 |
|
| 2007 |
Jönsson B, Lichtenberg F, Lundkvist J, Svedman C, Wilking N. The utilization of new oncology drugs: A global perspective Journal of Clinical Oncology. 25: 6612-6612. DOI: 10.1200/Jco.2007.25.18_Suppl.6612 |
0.406 |
|
| 2007 |
Jönsson B, Lichtenberg F, Wilking N. Reply to ‘Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Annals of Oncology 2007, vol 18, Suppl 3, pp1-75)’ by Michel P Coleman Annals of Oncology. 18: 1585-1587. DOI: 10.1093/Annonc/Mdm397 |
0.358 |
|
| 2007 |
Lichtenberg FR. Importation And Innovation Economics of Innovation and New Technology. 16: 403-417. DOI: 10.1080/10438590601002307 |
0.446 |
|
| 2007 |
Lichtenberg FR. Benefits and Costs of Newer Drugs: An Update Managerial and Decision Economics. 28: 485-490. DOI: 10.1002/Mde.1355 |
0.461 |
|
| 2007 |
Lichtenberg FR, Virabhak S. Pharmaceutical‐embodied technical progress, longevity, and quality of life: drugs as ‘Equipment for Your Health’ Managerial and Decision Economics. 28: 371-392. DOI: 10.1002/Mde.1347 |
0.424 |
|
| 2006 |
Lichtenberg FR. The impact of increased utilization of HIV drugs on longevity and medical expenditure: an assessment based on aggregate US time-series data. Expert Review of Pharmacoeconomics & Outcomes Research. 6: 425-36. PMID 20528512 DOI: 10.1586/14737167.6.4.425 |
0.398 |
|
| 2006 |
Lichtenberg FR. The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997 to 2003. Pharmacoeconomics. 24: 5-25. PMID 17266385 DOI: 10.2165/00019053-200624003-00002 |
0.314 |
|
| 2006 |
Lichtenberg FR. On "New Cardiovascular Drugs: Pattern of Use and Association with Non-Drug Health Expenditures". Inquiry : a Journal of Medical Care Organization, Provision and Financing. 43: 80-2; author reply 8. PMID 16838820 DOI: 10.5034/Inquiryjrnl_43.1.80 |
0.378 |
|
| 2006 |
Lichtenberg FR. Importation and Innovation National Bureau of Economic Research. DOI: 10.3386/W12539 |
0.442 |
|
| 2006 |
Lichtenberg FR. The Impact of New Laboratory Procedures and Other Medical Innovations on the Health of Americans, 1990-2003: Evidence from Longitudinal, Disease-Level Data National Bureau of Economic Research. DOI: 10.3386/W12120 |
0.407 |
|
| 2005 |
Lichtenberg FR. Availability of new drugs and Americans' ability to work. Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine. 47: 373-80. PMID 15824628 DOI: 10.1097/01.Jom.0000158724.28302.Ac |
0.355 |
|
| 2005 |
Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. International Journal of Health Care Finance and Economics. 5: 47-73. PMID 15714263 DOI: 10.1007/S10754-005-6601-7 |
0.462 |
|
| 2005 |
Lleras-Muney A, Lichtenberg FR. Are the More Educated More Likely to Use New Drugs Annals of Economics and Statistics. 671-696. DOI: 10.2307/20777592 |
0.338 |
|
| 2004 |
Lichtenberg FR. The Expanding Pharmaceutical Arsenal in the War on Cancer National Bureau of Economic Research. DOI: 10.3386/W10328 |
0.396 |
|
| 2004 |
Lichtenberg FR. Sources of U.S. longevity increase, 1960–2001 The Quarterly Review of Economics and Finance. 44: 369-389. DOI: 10.1016/J.Qref.2004.05.005 |
0.395 |
|
| 2003 |
Lichtenberg FR. The effect of new drug approvals on HIV mortality in the US, 1987-1998. Economics and Human Biology. 1: 259-66. PMID 15463977 DOI: 10.1016/S1570-677X(02)00031-X |
0.32 |
|
| 2003 |
Lichtenberg FR. The economic and human impact of new drugs. The Journal of Clinical Psychiatry. 64: 15-8. PMID 14680422 |
0.334 |
|
| 2003 |
Lichtenberg FR, Waldfogel J. Does Misery Love Company? Evidence from Pharmaceutical Markets Before and after the Orphan Drug Act Michigan Telecommunications and Technology Law Review. 15: 335-357. DOI: 10.3386/W9750 |
0.411 |
|
| 2003 |
Lehr W, Lichtenberg FR. Computer Use and Productivity Growth in Federal Government Agencies, 1987 to 1992 Journal of Industrial Economics. 46: 257-279. DOI: 10.1111/1467-6451.00071 |
0.324 |
|
| 2002 |
Lichtenberg FR. New drugs and lower costs. American Journal of Health-System Pharmacy : Ajhp : Official Journal of the American Society of Health-System Pharmacists. 59: 1894-5; author reply. PMID 12374084 DOI: 10.1093/Ajhp/59.19.1894A |
0.385 |
|
| 2002 |
Lleras-Muney A, Lichtenberg FR. The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs National Bureau of Economic Research. DOI: 10.3386/W9185 |
0.319 |
|
| 2002 |
Lichtenberg FR. The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output National Bureau of Economic Research. DOI: 10.3386/W9139 |
0.45 |
|
| 2002 |
Lichtenberg FR. Sources of U.S. Longevity Increase, 1960 - 1997 National Bureau of Economic Research. DOI: 10.3386/W8755 |
0.43 |
|
| 2002 |
Lichtenberg FR. The Effects of Medicare on Health Care Utilization and Outcomes Forum For Health Economics & Policy. 5: 27-52. DOI: 10.2202/1558-9544.1028 |
0.377 |
|
| 2002 |
Lichtenberg FR, Philipson TJ. The dual effects of intellectual property regulations: Within- and between-patent competition in the U.S. pharmaceuticals industry Journal of Law and Economics. 45: 643-672. DOI: 10.1086/374703 |
0.416 |
|
| 2001 |
Lichtenberg FR. Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS Health Affairs. 20: 241-251. PMID 11558710 DOI: 10.1377/Hlthaff.20.5.241 |
0.44 |
|
| 2001 |
Lichtenberg FR. The Effect of New Drugs on Mortality from Rare Diseases and HIV National Bureau of Economic Research. DOI: 10.3386/W8677 |
0.376 |
|
| 2001 |
Pottelsberghe Bv, Lichtenberg F. Does Foreign Direct Investment Transfer Technology Across Borders The Review of Economics and Statistics. 83: 490-497. DOI: 10.1162/00346530152480135 |
0.342 |
|
| 2000 |
Lichtenberg FR. The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey National Bureau of Economic Research. DOI: 10.3386/W8147 |
0.455 |
|
| 1999 |
Lehr B, Lichtenberg F. Information technology and its impact on firm-level productivity: evidence from government and private data sources, 1977-1993 Canadian Journal of Economics. 32: 335-362. DOI: 10.2307/136426 |
0.322 |
|
| 1999 |
Palia D, Lichtenberg F. Managerial ownership and firm performance: A re-examination using productivity measurement Journal of Corporate Finance. 5: 323-339. DOI: 10.1016/S0929-1199(99)00009-7 |
0.329 |
|
| 1998 |
Lichtenberg FR. Pharmaceutical Innovation, Mortality Reduction, and Economic Growth National Bureau of Economic Research. DOI: 10.3386/W6569 |
0.481 |
|
| 1998 |
Lichtenberg FR. The Allocation of Publicly-Funded Biomedical Research National Bureau of Economic Research. 565-590. DOI: 10.2139/Ssrn.44640 |
0.346 |
|
| 1998 |
Lichtenberg FR, Potterie BvPdl. International R&D spillovers: A comment European Economic Review. 42: 1483-1491. DOI: 10.1016/S0014-2921(97)00089-5 |
0.321 |
|
| 1996 |
Lichtenberg FR. The Effect of New Political Administration on Federal Government Productivity and Employment National Bureau of Economic Research. DOI: 10.3386/W5601 |
0.359 |
|
| 1996 |
Lichtenberg FR. The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality National Bureau of Economic Research. DOI: 10.3386/W5418 |
0.347 |
|
| 1995 |
Lichtenberg FR. The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis Economics of Innovation and New Technology. 3: 201-218. DOI: 10.1080/10438599500000003 |
0.345 |
|
| 1995 |
Lichtenberg FR. Economics of defense R&D Handbook of Defense Economics. 1: 431-457. DOI: 10.1016/S1574-0013(05)80017-1 |
0.303 |
|
| 1995 |
Lichtenberg FR. Labor Market Institutions, Liquidity Constraints, and Macroeconomic Stability Journal of Economic Behavior and Organization. 28: 145-154. DOI: 10.1016/0167-2681(94)00077-6 |
0.315 |
|
| 1992 |
Lichtenberg FR. R&D Investment and International Productivity Differences National Bureau of Economic Research. DOI: 10.3386/W4161 |
0.355 |
|
| 1992 |
Lichtenberg FR. Industrial De-Diversification and its Consequences for Productivity Journal of Economic Behavior and Organization. 18: 427-438. DOI: 10.2139/Ssrn.181153 |
0.326 |
|
| 1991 |
Lichtenberg FR, Siegel DS. The Impact of R&D Investment on Productivity - New Evidence Using Linked R&D-Lrd Data Economic Inquiry. 29: 203-229. DOI: 10.1111/J.1465-7295.1991.Tb01267.X |
0.332 |
|
| 1991 |
Bartel AP, Lichtenberg FR. The Age Of Technology And Its Impact On Employee Wages Economics of Innovation and New Technology. 1: 215-231. DOI: 10.1080/10438599100000003 |
0.312 |
|
| 1990 |
Lichtenberg FR, Siegel D. The Effect of Ownership Changes on the Employment and Wages of Central Office and Other Personnel The Journal of Law and Economics. 33: 383-408. DOI: 10.1086/467210 |
0.314 |
|
| 1990 |
Lichtenberg FR, Siegel DS. The Effects of Leveraged Buyouts on Productivity and Related Aspects of Firm Behavior Journal of Financial Economics. 27: 165-194. DOI: 10.1016/0304-405X(90)90025-U |
0.368 |
|
| 1990 |
Lichtenberg FR. Issues in measuring industrial R&D Research Policy. 19: 157-163. DOI: 10.1016/0048-7333(90)90045-8 |
0.334 |
|
| 1989 |
Lichtenberg FR, Siegel DS. The Effect of Takeovers on the Employment and Wages of Central-Office and Other Personnel National Bureau of Economic Research. DOI: 10.3386/W2895 |
0.323 |
|
| 1989 |
Lichtenberg FR, Kim M. The Effects of Mergers on Prices, Costs, and Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 National Bureau of Economic Research. DOI: 10.2139/Ssrn.181132 |
0.351 |
|
| 1989 |
Lichtenberg FR, Griliches Z. Errors of Measurement in Output Deflators Journal of Business & Economic Statistics. 7: 1-9. DOI: 10.1080/07350015.1989.10509704 |
0.323 |
|
| 1989 |
Lichtenberg FR. Ir&D Project Data and Theories of R&D Investment Journal of Economic Dynamics and Control. 13: 271-282. DOI: 10.1016/0165-1889(89)90022-5 |
0.307 |
|
| 1989 |
Lichtenberg FR. How Elastic is the Government's Demand for Weapons? Journal of Public Economics. 40: 57-78. DOI: 10.1016/0047-2727(89)90018-2 |
0.347 |
|
| 1988 |
Lichtenberg FR. Government Subsidies to Private Military R&D Investment: DOD's IR&D Policy National Bureau of Economic Research. DOI: 10.3386/W2745 |
0.336 |
|
| 1988 |
Bartel AP, Lichtenberg FR. Technical Change, Learning, and Wages National Bureau of Economic Research. DOI: 10.3386/W2732 |
0.3 |
|
| 1988 |
Lichtenberg FR. Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data The Review of Economics and Statistics. 70: 421-430. DOI: 10.2307/1926780 |
0.343 |
|
| 1987 |
Lichtenberg FR. The Effect of Government Funding on Private Industrial Research and Development: A Re-assessment Journal of Industrial Economics. 36: 97-104. DOI: 10.2307/2098599 |
0.332 |
|
| 1987 |
Bartel AP, Lichtenberg FR. The Comparative Advantage of Educated Workers in Implementing New Technology The Review of Economics and Statistics. 69: 1-11. DOI: 10.2307/1937894 |
0.354 |
|
| 1987 |
Lichtenberg FR. Changing market opportunities and the structure of R & D investment: The case of energy Energy Economics. 9: 154-158. DOI: 10.1016/0140-9883(87)90021-1 |
0.344 |
|
| 1986 |
Lichtenberg FR. Private Investment in R&D to Signal Ability to Perform Government Contracts National Bureau of Economic Research. DOI: 10.3386/W1974 |
0.344 |
|
| 1986 |
Lichtenberg FR. Energy prices and induced innovation Research Policy. 15: 67-75. DOI: 10.1016/0048-7333(86)90002-8 |
0.345 |
|
| 1985 |
Bartel AP, Lichtenberg FR. The Comparative Advantage of Educated Workers in Implementing New Technology: Some Empirical Evidence National Bureau of Economic Research. DOI: 10.3386/W1718 |
0.355 |
|
| 1982 |
Griliches Z, Lichtenberg FR. R and D and Productivity at the Industry Level: Is There Still a Relationship? National Bureau of Economic Research. DOI: 10.3386/W0850 |
0.338 |
|
| Show low-probability matches. |